# US 2016/0355787 A1 · Endocrine precursor cells, pancreatic hormone-expressing cells and methods of production

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0355787 A1
- Document ID: US20160355787A1
- Status: Published application
- Kind: A1
- Application number: 15/173,316
- Filed: 2016-06-03
- Published: 2016-12-08
- Earliest claimed: 2006-03-02
- Assignees: ViaCyte, Inc.
- Applicants: ViaCyte, Inc.
- Inventors: Kevin A. D'Amour; Anne Bang; Emmanuel E. Baetge
- Web page: https://patentgrep.com/patent/US20160355787A1

## CPC

- C12N 5/0676: {Pancreatic cells}
- A61K 35/39: Pancreas; Islets of Langerhans (Langerhans cells of epidermis A61K35/36)
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/48: of the pancreatic hormones
- C12N 5/0678: {Stem cells; Progenitor cells; Precursor cells}
- C12N 2500/38: Vitamins
- C12N 2501/10: Growth factors
- C12N 2501/105: Insulin-like growth factors [IGF]
- C12N 2501/115: Basic fibroblast growth factor (bFGF, FGF-2)
- C12N 2501/119: Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
- C12N 2501/12: Hepatocyte growth factor [HGF]
- C12N 2501/15: Transforming growth factor beta (TGF-β)
- C12N 2501/16: Activin; Inhibin; Mullerian inhibiting substance
- C12N 2501/33: Insulin
- C12N 2501/335: Glucagon; Glucagon-like peptide [GLP]; Exendin
- C12N 2501/385: of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
- C12N 2501/41: Hedgehog proteins; Cyclopamine (inhibitor)
- C12N 2501/415: Wnt; Frizzeled
- C12N 2501/42: Notch; Delta; Jagged; Serrate
- C12N 2501/58: Adhesion molecules, e.g. ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand)
- C12N 2501/734: Proteases (EC 3.4.)
- C12N 2501/999: Small molecules not provided for elsewhere
- C12N 2506/02: from embryonic cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are cell cultures and enriched cell populations of endocrine precursor cells, immature pancreatic hormone-expressing cells and mature pancreatic hormone-expressing cells. Also disclosed herein are methods of producing such cell cultures and cell populations.

## Claims

### Claim 1

An in vitro method of making a population of human PDX1-positive pancreatic endoderm cells, comprising:
a) obtaining a population of human definitive endoderm cells; and
b) contacting the population of human definitive endoderm cells from step (a) with a retinoid, thereby making the population of human PDX1-positive pancreatic endoderm cells.

### Claim 2 (depends on 1)

The method of claim 1, comprising producing the population of human definitive endoderm cells by contacting a population of human pluripotent cells with at least one growth factor of the TGFβ superfamily.

### Claim 3 (depends on 2)

The method of claim 2, further comprising removing the growth factor of the TGFβ superfamily prior to contacting the population of human definitive endoderm cells from step (a) with the retinoid.

### Claim 4 (depends on 1)

The method of claim 1, further comprising contacting the population of human definitive endoderm cells from step (a) with a gamma secretase inhibitor.

### Claim 5 (depends on 4)

The method of claim 4, wherein the gamma secretase inhibitor is DAPT.

### Claim 6 (depends on 1)

The method of claim 1, further comprising transplanting the population of human PDX1-positive endoderm cells into a host to mature into insulin secreting cells.

### Claim 7 (depends on 6)

The method of claim 6, wherein the insulin secreting cells form islet-like cell clusters.

### Claim 8 (depends on 7)

The method of claim 7, wherein the islet-like cell clusters comprise singly-positive insulin cells.

### Claim 9 (depends on 1)

The method of claim 1, wherein the population of human PDX1-positive pancreatic endoderm cells expresses NGN3 and does not substantially express a marker selected from the group consisting of ghrelin, glucagon, insulin, and islet amyloid polypeptide (IAPP).

### Claim 10 (depends on 1)

The method of claim 1, further comprising contacting the population of human PDX1-positive pancreatic endoderm cells with a factor selected from the group consisting of nicotinamide (NIC), exendin 4 (Ex4), hepatocyte growth factor (HGF), insulin-like growth factor (IGF) and combinations thereof.

### Claim 11 (depends on 1)

The method of claim 1, wherein the retinoid is retinoic acid.

### Claim 12

An in vitro composition comprising a population of human PDX1-positive pancreatic endoderm cells that express NGN3 and a carrier.

### Claim 13 (depends on 12)

The composition of claim 12, wherein the population of human PDX1-positive pancreatic endoderm cells is derived from a population of human pluripotent cells cultured with activin A.

### Claim 14 (depends on 12)

The composition of claim 12, wherein the population of human PDX1-positive pancreatic endoderm cells is transplanted and mature in vivo to insulin secreting cells.

### Claim 15 (depends on 14)

The composition of claim 14, wherein the insulin secreting cells form islet-like cell clusters.

### Claim 16 (depends on 15)

The composition of claim 15, wherein the islet-like cell clusters contain singly-positive insulin cells.

### Claim 17 (depends on 12)

The composition of claim 12, further comprising a factor selected from the group consisting of a retinoid, a gamma secretase inhibitor, a growth factor of the fibroblast growth factor family, nicotinamide (NIC), exendin 4 (Ex4), hepatocyte growth factor (HGF), insulin-like growth factor (IGF) and combinations thereof.

### Claim 18 (depends on 12)

The composition of claim 12, wherein the population of human PDX1-positive pancreatic endoderm cells that express NGN3 further expresses NKX2.2.

### Claim 19 (depends on 12)

The composition of claim 12, wherein the population of human PDX1-positive pancreatic endoderm cells that express NGN3 does not substantially express a marker selected from the group consisting of ghrelin, glucagon, insulin, and IAPP.

### Claim 20

A composition comprising a population of PDX1-positive pancreatic endoderm cells that express NGN3 on a biocompatible scaffold.
